Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CANbridge Pharmaceuticals Inc. (1228.HK)
Beijing, CN
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +21.56% | +4.10% | -2.87% | -30.72% | -2.40% | -20.70% | +1,392.65% | +21.56% | -77.19% | -77.19% | -77.19% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-41.3% Q4'25: -31.2% (vs Q4'24)
-
EPS growth Biotechnology: +29.7%+102.9% ★ Q4'25: +79.7% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-89.6% Q4'25: +0.0% (vs Q4'24)
-
EBIT margin Biotechnology: +0.0%-185.5% Q4'25: -183.3% (vs Q4'24)
-
ROIC Biotechnology: -16.1%— Q4'25: +25.9% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+7.6% Q4'25: +13.5% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.20× Q4'25: -0.18× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
31.16M
est: 46.15M (-32.5%)
|
78.97M
est: 87.68M (-9.9%)
|
102.87M
est: 97.31M (+5.7%)
|
85.10M
est: 129.95M (-34.5%)
|
49.98M
est: 149.94M (-66.7%)
|
310.78M
310.78M – 310.78M
+107.3% YoY
|
| EBITDA |
-1.06B
est: -46.15M (-2,192.9%)
|
-454.63M
est: -87.68M (-418.5%)
|
-341.43M
est: -97.31M (-250.9%)
|
-328.69M
est: -129.95M (-152.9%)
|
-78.98M
est: -149.94M (+47.3%)
|
-310.78M
-310.78M – -310.78M
-107.3% YoY
|
| EBIT |
-1.07B
est: -46.15M (-2,226.9%)
|
-476.61M
est: -87.68M (-443.6%)
|
-369.89M
est: -97.31M (-280.1%)
|
-340.52M
est: -129.95M (-162.0%)
|
-92.70M
est: -149.94M (+38.2%)
|
-310.78M
-310.78M – -310.78M
-107.3% YoY
|
| Net Income |
-1.08B
est: -519.07M (-107.5%)
|
-483.48M
est: -498.94M (+3.1%)
|
-378.84M
est: -408.30M (+7.2%)
|
-442.62M
est: -269.47M (-64.3%)
|
14.82M
est: -348.93M (+104.2%)
|
-317.02M
-317.02M – -317.02M
+9.1% YoY
|
| SGA |
246.27M
est: 225.66M (+9.1%)
|
195.69M
est: 428.72M (-54.4%)
|
173.50M
est: 300.37M (-42.2%)
|
143.06M
est: 401.11M (-64.3%)
|
84.20M
est: 462.80M (-81.8%)
|
959.25M
959.25M – 959.25M
+107.3% YoY
|
| EPS |
-11.43
est: -1.22 (-835.5%)
|
-1.14
est: -1.17 (+2.9%)
|
-0.89
est: -0.89 (+0.4%)
|
-1.04
est: -0.59 (-76.3%)
|
0.03
est: -0.76 (+103.7%)
|
-0.69
-0.69 – -0.69
+9.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Small-Cap Equity Factor ETF ISCF | 0.02% | 151.0K | 0.24% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Qun Xue | Founder, Chairman of the Board, Chief Executive Officer & Member of Strategic Advisory Board | 4M | — |
| Gerald F. Cox | Chief Development Strategist & Interim Chief Medical Officer | — | — |
| Jason West | Head of Global Gene Therapy Research | — | — |
| Jeff Kou | Head of Clinical Operations and Senior Director of R&D Strategy & Portfolio Management | — | — |
| Joe Shen | Chief Operating Officer | — | male |
| Lillian Zhang | Senior Director & Head of Finance Operations and Controller | — | female |
| Qian Ma | Vice President, Company Secretary & General Counsel | — | female |
| Rebecca Zhang | Chief Regulatory Advisor | — | female |
| Suya Gao | Acting Head of Commercial Operations of Mainland China | — | female |
| Chris Chen | Senior Vice President of Human Resources | — | female |
| Will Wang | Executive Director of Production | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1228.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
